Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression
- 19 September 2005
- journal article
- Published by Springer Nature in Oncogene
- Vol. 25 (2) , 304-309
- https://doi.org/10.1038/sj.onc.1209026
Abstract
Mutations in the TP53 tumor suppressor gene are the most frequent genetic alteration in human cancers. These alterations are mostly missense point mutations that cluster in the DNA binding domain. There is growing evidence that many of these mutations generate mutant p53 proteins that have acquired new biochemical and biological properties. Through this gain of function activity, mutant p53 is believed to contribute to tumor malignancy. The purpose of our study was to explore mutant p53 as a target for novel anticancer treatments. To this aim, we inhibited mutant p53 expression by RNA interference in three different cancer cell lines endogenously expressing mutant p53 proteins, and evaluated the effects on the biological activities through which mutant p53 exerts gain of function. We found that depletion of mutant p53 reduces cell proliferation, in vitro and in vivo tumorigenicity, and resistance to anticancer drugs. Our results demonstrate that mutant p53 knocking down weakens the aggressiveness of human cancer cells, and provides further insight into the comprehension of mutant p53 gain of function activity in human tumor.Keywords
This publication has 20 references indexed in Scilit:
- P53 and PrognosisCell, 2005
- p53‐R175H mutant gains new function in regulation of doxorubicin‐induced apoptosisInternational Journal of Cancer, 2004
- Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of FunctionCancer Research, 2004
- Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genesOncogene, 2004
- Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutantsOncogene, 2003
- Chemosensitivity linked to p73 functionCancer Cell, 2003
- A System for Stable Expression of Short Interfering RNAs in Mammalian CellsScience, 2002
- Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1Journal of Biological Chemistry, 2001
- Mutant p53 protein expression interferes with p53-independent apoptotic pathwaysOncogene, 1998
- `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domainOncogene, 1998